Login / Signup

Regions of homozygosity confer a worse prognostic impact in myelodysplastic syndrome with normal karyotype.

Mar MalloHeinz TuechlerLeonor ArenillasSophie RaynaudThomas CluzeauLee-Yung ShihChiang Tung-LiangChristina GansterKatayoon ShirneshanDetlef HaaseMartí MascaróLaura PalomoJosé CerveraEsperanza SuchNicola TrimSally JeffriesEmma RidgwayGiovanni MarconiGiovanni MartinelliFrancesc Solé
Published in: EJHaem (2023)
Half of the myelodysplastic syndromes (MDS) have normal karyotype by conventional banding analysis. The percentage of true normal karyotype cases can be reduced by 20-30% with the complementary application of genomic microarrays. We here present a multicenter collaborative study of 163 MDS cases with a normal karyotype (≥10 metaphases) at diagnosis. All cases were analyzed with the ThermoFisher® microarray (either SNP 6.0 or CytoScan HD) for the identification of both copy number alteration(CNA) and regions of homozygosity (ROH). Our series supports that 25 Mb cut-off as having the most prognostic impact, even after adjustment by IPSS-R. This study highlights the importance of microarrays in MDS patients, to detect CNAs and especially to detect acquired ROH which has demonstrated a high prognostic impact.
Keyphrases
  • copy number
  • mitochondrial dna
  • genome wide
  • end stage renal disease
  • dna methylation
  • newly diagnosed
  • gene expression
  • prognostic factors
  • patient reported outcomes